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Abstract Accumulating evidence suggests that certain
features of hepatitis C virus (HCV), especially its high
genetic variability, might be responsible for the low
efﬁciency of anti-HCV treatment. Here, we present a bio-
informatic analysis of HCV-1a populations isolated from
23 children with chronic hepatitis C (CHC) subjected to
interferon–ribavirin therapy. The structures of the viral
quasispecies were established based on a 132-amino-acid
sequence derived from E1/E2 protein, including hyper-
variable region 1 (HVR1). Two types of HCV populations
were identiﬁed. The ﬁrst type, found in non-responders,
contained a small number of closely related variants. The
second type, characteristic for sustained responders, was
composed of a large number of distantly associated equal-
rank variants. Comparison of 445 HVR1 sequences showed
that a signiﬁcant number of variants present in non-
responding patients are closely related, suggesting that
certain, still unidentiﬁed properties of the pathogen may be
key factors determining the result of CHC treatment.
Introduction
At present, about 3% of the human population is infected
with hepatitis C virus (HCV). The ﬁrst, acute stage of HCV
infection is usually asymptomatic [11]. However, only
15–30% of the infected eliminate the virus. The remaining
patients develop chronic hepatitis C (CHC). Despite two
decades of intensive studies, no obvious correlations have
been found between the parameters describing CHC
patients and the course of infection or the outcome of
therapy [1]. Instead, HCV genotype and virus load were
conﬁrmed to be important factors affecting the ﬁnal result
of antiviral treatment. Individuals infected with genotype 2
or 3 and those with a low level of viremia respond better to
the therapy [14, 18, 24]. This indicates that certain features
of the virus, rather than those of the host, may actually be
critical for CHC treatment.
Recently, it has become increasingly clear that one of the
key factors making CHC therapy so difﬁcult is the unusual
genetic polymorphism of the virus [8, 27]. The major cause
of this polymorphism is the effective, but error-prone rep-
lication of the RNA genome [8]. Consequently, HCV does
not form a homogenous population but exists as a quasi-
species [8, 27]. The latter is deﬁned as a pool of phyloge-
netically related but genetically slightly distinct variants
present in a single infected organism [3, 4]. All variants are
subjected to continuous selection; therefore, only the most
ﬁt are able to survive and spread [8]. Several regions of
the HCV genome demonstrate an especially high level of
variability. Among them, hypervariable region 1 (HVR1),
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tein, is thought to be the most heterogeneous one.
A number of attempts have been made in recent years to
ﬁnd a correlation between the complexity of HCV quasi-
species and the outcome of CHC therapy in adults. The
diversity of viral populations was usually evaluated based
on two regions of the HCV genome: E1/E2 (including
HVR1), and NS5A. As a result, it has been postulated that
HCV quasispecies display decreased heterogeneity in
patients who develop a sustained virological response
[5, 20, 25, 30]. In contrast, little is currently known about
the structure of the HCV population in children. This issue
raises many important questions, especially since the nat-
ural history and clinical features of HCV infection in
children and adults are different. A milder, often asymp-
tomatic liver disease with a normal or slightly elevated
level of alanine aminotransferase activity impedes the
diagnosis of HCV infection in childhood [15]. Conse-
quently, the percentage of CHC in pediatric patients is
probably underestimated. In addition, available reports
concerning HCV quasispecies in children are usually based
on only a few cases. Some of these reports refer to viral
populations in untreated children [6, 12], the others to HCV
quasispecies in patients coinfected with human immuno-
deﬁciency virus (HIV) [2, 26].
In this paper, we present an analysis of HCV quasispe-
cies isolated from 23 children with CHC, all infected with
the same HCV subtype (1a). For each of them, the structure
of the virus population was determined just before anti-
HCV treatment and 2 weeks later.
Materials and methods
Patient qualiﬁcation and treatment
The studies included two groups of children with chronic
hepatitis C (all infected with HCV-1a). The ﬁrst group
included 10 patients subjected to combined interferon–
ribavirin therapy in 2004 (patients designated P1-01 to
P1-10). The second group comprised 13 patients who were
treated in the same way, but 1 year later (patients P2-02 to
P2-28). The study conforms to the ethical guidelines of the
World Medical Association Declaration of Helsinki. In
each case, both parents and children (12 years or older)
provided informed consent for treatment and participation
in the study. Before the commencement of the project, an
appropriate approval from the Bioethical Commission of
Karol Marcinkowski University of Medical Sciences was
obtained. The inclusion criteria were as follows: (1) the
detection of anti-HCV antibodies and HCV RNA in the
serum for at least 6 months; (2) periodically or continu-
ously elevated ALT activity; and (3) histopathological
signs of chronic hepatitis [9]. The treatment was conducted
according to the following schema: interferon alpha 2b was
administered in 3 million unit doses subcutaneously 3
times a week; ribavirin, in doses of 15 mg/kg per day
orally [9]. The level of HCV RNA accumulation was
determined for each patient, just before therapy (T0) and
then after 24 (T24), 48 (T48) and 72 (T72) weeks, using an
Amplicor HCV Monitor Test v. 2.0 (Roche). The patients
with a positive result (a detectable amount of HCV RNA)
at T24 were excluded, whereas the others were treated for
24 more weeks. After 72 weeks of treatment and follow-
up, patient response to combined interferon–ribavirin
therapy was evaluated. It was considered: (1) sustained
(SR) if HCV RNA was not detected at T24, T48 and T72;
(2) transient (TR) if HCV RNA was not detected at T24 but
appeared again at T48 and was still present at T72 or HCV
RNA was not detected at T24 and T48 and appeared at
T72; (3) no response (NR) if HCV RNA was detected at
T24, T48 and T72. Anti-HCV antibodies were detected
in sera by fourth-generation ELISA (ETI-AB-HCVK-4,
DiaSorin).
Analysis of the HCV quasispecies structure
The structure of the HCV population was examined sepa-
rately for each of 23 patients before therapy (T0) and
2 weeks after therapy had begun (T2). To this end, HCV
RNA was isolated from the patients’ sera, and a 462-nt
portion of the E1/E2 coding sequence (a fragment located
in the HCV genome between positions 1425 and 1886) was
ampliﬁed by the RT-PCR method [19] using a OneStep
RT-PCR Kit (QIAGEN). All nucleotide positions refer to
the standard HCV-1a genome sequence, accession number
AF009606.
The following pairs of primers were used for RT-PCR:
(1) Outer: F1: 50CAG(CT)T(AG)CTCCGGATCCCAC
AAGC30 and R1: 50ACGTCCGTCTCATT(CT)(TG)
C(AC)CCCCA30;
(2) Inner: F2: 50TCTGGATCCTATTCCATGGTGGGG
AACTGG30 and R2: 50AATGAATTCTACAACAGG
GCT(TG)GG(AG)GTGAA30 (modiﬁed from ref. 19).
Letters in parentheses indicate degenerate positions.
The RT-PCR products were cloned into the pUC vector,
and at least 20 randomly selected clones were sequenced
per population. The nucleotide sequences obtained were
translated in silico into amino acid sequences. A bioin-
formatic analysis was conducted separately for each pop-
ulation (represented by 20 randomly selected clones at each
time point; over 900 sequences in total). This was done
using the predicted amino acid sequence of the entire
amplicon (excluding primer hybridization sites) or its
fragments: hypervariable region 1 (HVR1, located in the
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123HCV genome between positions 1491 and 1571) or the
remaining portion of the ampliﬁed E1/E2 coding sequence
(non-HVR1). The composition of the HCV quasispecies
was established by direct comparison of the predicted
amino acid sequences. As a result, the number of different
variants within the population and the contribution of each
individual variant to the examined population were estab-
lished. Clones containing nonsense and frameshift muta-
tions were excluded. Consequently, the number of variants
analyzed was reduced for some populations. Genetic
diversity was assessed based on the Hamming distance,
which is deﬁned as the number of amino acid differences
between two sequences. The genetic diversity of a popu-
lation was expressed as a mean Hamming distance (MHD),
an average value taken for all sequence pairs. Statistical
analysis was performed using the Statistica 8.0 package.
The values of MHD determined for all patients were
divided into two groups, (1) non-responders ? transient
responders and (2) sustained responders, and analyzed
using the non-parametric U Mann–Whitney test (because
the results of the Shapiro–Wilk test were negative). Phy-
logenetic trees were created using the maximum-likelihood
method with 500 boostrap replicates. WAG and HKY85
substitution models were employed for amino acid and
nucleotide sequences, respectively. Selection tests were
made using the internal ﬁxed effects likelihood (IFEL) and
single likelihood ancestor counting (SLAC) approaches,
available at www.datamonkey.org [23]. To count the glo-
bal (SLAC) and codon-speciﬁc (IFEL) dN/dS ratios, the
HKY85 model of nucleotide substitution and neighbor-
joining trees [17, 28] were utilized, with a signiﬁcance
level value of 0.1. All available sequences of viral variants
were analyzed. A consensus amino acid sequence was
produced using the Consensus tool available at the Los
Alamos HCV Sequence Database http://hcv.lanl.gov/content/
hcv-db/consensus/consensus.html [16].
Results
Complexity of HCV quasispecies
The complexity of HCV quasispecies was assessed twice
for all 23 patients: just before treatment (T0) and 2 weeks
later (T2). The number of different variants within each
population and each population’s genetic diversity were
determined. The analysis was carried out for the entire
ampliﬁed E1/E2 region, and then separately for its two
fragments: HVR1 and the remaining portion of E1/E2
(non-HVR1). Finally, three sets of data describing the
complexity of HCV quasispecies (Online Resources 1, 2,
3, 4) were examined in relation to parameters character-
izing the patients’ response to anti-HCV therapy, the level
of HCV RNA accumulation in their blood and the level of
ALT activity (Table 1). As a result, a signiﬁcant correla-
tion was only found between the outcome of antiviral
therapy and HCV quasispecies complexity if the latter was
determined at T0 and based solely on HVR1. In this case,
HCV populations isolated from non-responders and tran-
sient responders were composed of a markedly lower
number of variants (mean: 6,462; SD: 3,406) than popu-
lations derived from sustained responders (mean: 11; SD:
3,496; Fig. 1a; Online Resource 3). The level of genetic
diversity (expressed by the mean Hamming distance:
MHD) differed signiﬁcantly (p\0.05) between sustained
responders and children who failed to clear the virus
(non-responders plus transient responders). The obtained
p values were equal to 0.0011 and 0.0039 for T0 and T2,
respectively. The MHD was lower for HCV populations
derived from non-responders and transient responders
(mean at T0: 1,899; SD: 2,043) and higher for quasispecies
coming from sustained responders (mean at T0: 6,152; SD:
2,486; Fig. 1b). Only for one population isolated from a
child classiﬁed as a non-responder did MHD reach a rel-
atively high value of 4.93. For two quasispecies derived
from sustained responders, the MHD value was consider-
ably below average: 0.79 and 3.14. The analysis performed
for the whole ampliﬁed E1/E2 region revealed tendencies
similar to those observed for HVR1. However, they were
much less pronounced (Online Resource 4).
The 2-week interferon–ribavirin therapy differentially
inﬂuenced the composition of the viral populations. At T2,
an increase in the number of variants was observed in
the majority of populations present in non-responders. A
decreasewasobservedinthosefromsustainedresponders.A
closer analysis of individual variants revealed diverse pat-
terns of quasispecies evolution over the 2 weeks of treat-
ment. Only in some populations was the contribution of the
dominatingvariantincreased.Forothers,weobservedoneof
the following: (1) a lack of any substantial changes in the
populationstructure;(2)theformationofnewco-dominants;
(3) the extinction of the dominant variant or (4) the devel-
opment of new dominating variants that had not been iden-
tiﬁedbeforetreatment(OnlineResource3).Theinﬂuenceof
the applied therapy on MHD was quite diverse. It was not
related to the patients’ response to antiviral treatment.
Phylogenetic analysis
To determine not only the diversity of variants constituting
each individual HCV population but also the relationships
between them, phylogenetic trees were constructed for all
of the quasispecies (Fig. 2; Online Resources 5, 6, 7).
Again, the most signiﬁcant correlation between the outcome
of antiviral therapy and the character of HCV phylogeny
was found for trees produced on the basis of HVR1
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123identiﬁed at T0. Trees depicting populations derived from
non-responding children were compact, almost monophy-
letic. Interestingly, the only quasispecies from this group for
which a visibly higher MHD value was obtained (P2-23)
was found to be composed of two intrinsically homoge-
neous subpopulations. In contrast, trees based on popula-
tions isolated from sustained responders were very
extended, without any clear clusters.
After the 2 weeks of treatment (T2), the topology of the
phylogenetic trees remained mostly unaffected. Some
changes could be observed almost exclusively for popula-
tions isolated from sustained responders. In these cases, a
reduction or an increase in the degree of tree branching was
observed. An analogous analysis based on the entire E1/E2
region or its non-HVR1 fragment did not yield conclusive
results (Online Resources 5 and 6). This again conﬁrmed
that HVR1 best reﬂects differences between quasispecies
obtained from children with different responses to anti-
HCV therapy.
Inter-quasispecies HVR1 conservation
To evaluate the relationships between HVR1 variants
present in different quasispecies at T0, an integrated
phylogenetic tree was constructed. It was obtained based
on all (445) variants identiﬁed in 23 HCV populations.
While variants from sustained responders were noticeably
dispersed, those derived from patients responding tran-
siently and from non-responders tended to concentrate in
clusters (Online Resource 8). Astonishingly, the variants
isolated from ten non-responding children clustered into
only seven groups. A more detailed analysis revealed that
one of them, cluster 1, encompassed variants from ﬁve
patients. Together with the closely related cluster 2, they
constituted a pair grouping variants derived from six epi-
demiologically distinct viral populations (P1-01, P1-02,
P1-03, P1-05, P2-05 and P2-19) (Online Resource 8;
Fig. 3a). This observation suggested that HVR1 variants
formed in different non-responding patients were often
identical or quite similar. All of the analyses presented
above were based on comparisons of amino acid sequen-
ces. To verify the results concerning inter-quasispecies
conservation of HVR1, nucleotide sequences of variants
grouping in clusters 1 and 2 were compared. Both phylo-
genetic analysis (Fig. 3b) and sequence alignment revealed
population-speciﬁc differences occurring at the nucleotide
level. Consequently, consensus sequences unique to each
quasispecies could be generated (Fig. 4). This provided
Table 1 Clinical, biochemical
and virological characteristics
of children with chronic
hepatitis C subjected to
interferon–ribavirin therapy
a Female,
bMale,
cNo response,
dTransient response,
eSustained
response, *Patient previously
subjected to immunosuppressive
treatment of an oncologic
disease, ? Anti-HCV positive,
- Anti-HCV negative
Patient
no.
Age
(years)
Sex Pretreatment
viremia
(copies/mL)
Pretreatment
ALT (IU/L)
Pretreatment anti-HCV
antibodies (fourth-
generation ELISA)
Treatment
response
P1-01 8 F
a 7,803,000 44 ? NR
c
P1-02 8 M
b 14,148,000 35 ? NR
P1-03 12 F 804,600 59 ? NR
P1-04 17 M 9,072,000 19 ? TR
d
P1-05 14 M 9,018,000 29 ? NR
P1-06 11 F 337,500 32 ? SR
e
P1-07 9 M 631,800 87 ? TR
P1-08 10 F 858,600 30 ? SR
P1-09 10 M 804,600 20 ? SR
P1-10 10 F 46,440 48 ? SR
P2-02 12 F 768,600 17 ? SR
P2-04 13 M 11,280,000 315 ? NR
P2-05* 11 F 2,170,000 53 - NR
P2-08 16 F 1,870,000 40 ? SR
P2-10* 11 M 2,670,000 45 - NR
P2-17 8 M 56,300,000 19 ? SR
P2-18 15 F 696,000 54 ? SR
P2-19 10 F 726,000 35 ? NR
P2-20 15 F 152,000 37 ? SR
P2-22 11 M 713,000 35 ? SR
P2-23 10 M 840,000 63 ? NR
P2-24 16 F 286,000 28 ? TR
P2-28* 14 F 365,000 51 - NR
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123additional evidence that the similarity/identity between
HVR1 variants was not caused by cross-contamination.
These results suggest that the similar/identical HVR1
variants that were identiﬁed were already optimal: their
appearance was strictly connected with the lack of patients’
response to the antiviral therapy. None of them were found
in populations isolated from patients with transient and
sustained response (Online Resource 8). These variants
were present in viral populations before treatment and
persisted at least through the ﬁrst 2 weeks of its duration
(Online Resource 3: identity of dominating variants
between T0 and T2).
Selection pressure as a factor shaping the HCV
population
A viral quasispecies is subjected to natural selection
throughout its existence within the host. Positive selection
acts towards introducing nonsynonymous mutations and
increasing the diversity of the population. In contrast,
negative selection favors synonymous changes and restricts
the process of diversiﬁcation, keeping the population more
homogenous. In order to determine what kind of selection
pressure shaped the viral population in the group of
patients studied, the nucleotide sequences of all HVR1
variants identiﬁed at T0 and T2 were compared. The
analysis included only the HVR1 region because it best
reﬂected differences between populations derived from
patients with different responses to antiviral therapy. Ini-
tially, the nucleotide sequences of 904 HVR1 variants
derived from 23 patients were divided (according to the
sampling time and type of response to the antiviral therapy)
into six groups: NR-T0, NR-T2, TR-T0, TR-T2, SR-T0,
SR-T2 (NR—no response, TR—transient response, SR—
sustained response). First, the number of synonymous and
nonsynonymous substitutions per site (dS and dN, respec-
tively) was established. Then, the global and codon-spe-
ciﬁc dN/dS ratio (parameter characterizing selection
pressure) was determined (Table 2). Values lower than 1
are characteristic of negative selection; values higher than
1, of positive selection. Under positive selection, only 2
and 4 codons were identiﬁed within the sequences of
variants forming the NR-T0 and NR-T2 groups, respec-
tively; under negative selection, 4 and 5 codons were
identiﬁed in the same sequences. A similar trend was
detected among HVR1 sequences from the TR-T0 and
TR-T2 groups. In contrast, as many as 10 codons were
subjected to positive selection, and only 2 were subjected
to negative selection in variants belonging to the SR-T0
group. In SR-T2, 9 codons were found to be under positive
selection and 4 codons were under negative selection. The
global character of selection within the entire HVR1 was
negative in non-responders and transient responders. It was
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Fig. 1 Complexity of HCV quasispecies (determined based on the
HVR1 amino acid sequence). a Number of different variants. Circular
diagrams show the composition of the individual HCV populations
derivedfromtherepresentative:non-responder(NR),transientresponder
(TR) and sustained responder (SR). Each individual variant is repre-
sentedbyonesector.Sectorsrepresentingvariantsidentiﬁedexclusively
at T0 or T2 are white and gray, respectively. Sectors representing
identical variantsfound atboth T0and T2in one patient(notindifferent
patients) are indicated with other colors. Numbers accompanying the
diagramsindicatehowfrequentlyeachvariantwasidentiﬁed(thelackof
a number indicates that the sequencewas found only once). The number
of different variants (NDV) found in each population is given below the
diagram. b Genetic diversity. The mean Hamming distance was
calculated separately for each viral population based on 20 HVR1
clonesrandomlyselectedatT0andT2.Thecolorsofthebarscorrespond
to the three types of responses of the patients to the treatment: red no
response; blue transient response; and green sustained response
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123strongly positive in sustained responders. After 2 weeks of
therapy, the number of selected sites increased in all three
groups, but the character of the pressure operating globally
in HVR1 remained unchanged. This observation clearly
indicates that selection pressure is the key modulator of
HCV quasispecies diversity. Strikingly, the commonly
described process of continuous selection and adaptation
was apparently ongoing only in sustained responders. In
contrast, the evolution of the quasispecies in non-
responding patients seemed to be rigorously conﬁned, most
probably by the necessity for maintaining deﬁned HVR1
properties.
Discussion
In spite of ample evidence that high genetic variability of
RNA viruses affects host-virus interactions, the question
concerning the correlation between particular parameters
characterizing HCV quasispecies and the course of CHC or
results of its treatment remains open. Considering earlier
studies, we decided to focus our investigations on the 462-nt
fragment of the E1/E2 region of the HCV genome, com-
prising HVR1. Previous analyses of the HCV quasispecies
have usually involved several genotypes (often all six),
although it was known that HCV-2 and -3 are eliminated
more frequently than HCV-1 [7]. The latter observation
suggest that the results obtained for one genotype cannot be
extrapolated to the others, and that is why our analysis
involved a group of 23 children with CHC, all of whom
were infected with HCV-1a and qualiﬁed for combined
interferon–ribavirin therapy.
The collected data revealed an apparent correlation
between the ﬁnal effect of CHC therapy and the HVR1
polymorphism observed just before treatment (at T0).
Accordingly, we distinguished two types of HCV
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Fig. 2 Phylogenetic analysis of individual HCV quasispecies. Rep-
resentative phylogenetic trees obtained for HCV populations isolated
at T0 and T2 from non-responders (NR), transient responders (TR)
and sustained responders (SR). The trees were constructed based on
HVR1 amino acid sequences. The percentage of trees in which the
variants clustered together is indicated above the branches (values
lower than 50% were removed). Branch lengths are proportional to
the number of substitutions per site
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Fig. 3 Inter-quasispecies
conservation of HVR1 variants
isolated from non-responders.
Phylogenetic analysis was
carried out with selected HCV
quasispecies isolated from non-
responders at T0. Phylogenetic
trees were constructed for
HVR1 amino acid (a) and
nucleotide (b) sequences. The
individual sequences are named
according to the following
schema: HVR-patient-number-
clone-number; e.g. HVR-P1-03-
1-21, where ‘P1-03’ indicates
the patient number, while ‘1-21’
refers to the clone number. In
addition, the names are
accompanied by geometrical
symbols. All sequences
representing the same
quasispecies are marked with
the same symbol. The
percentage of trees in which the
variants clustered together is
indicated above the branches
(values lower than 50% were
removed). Branch lengths are
proportional to the number of
substitutions per site
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123quasispecies. The ﬁrst type, formed by one dominating
variant accompanied by a small number of closely related
ones, was characteristic of the non-responding patients.
The second type, composed of a large number of distantly
associated equally ranked variants was typical for sustained
responders. In both groups of patients, the level of HCV
RNA varied over a wide range (Table 1), and we did not
ﬁnd a statistically signiﬁcant correlation between the
accumulation of viral RNA and HCV quasispecies vari-
ability or therapy outcome. Unfortunately, the amount of
information concerning the correlation between the com-
plexity of HCV quasispecies and the efﬁcacy of anti-HCV
treatment in children is still very limited. The existence of
two patterns of HCV evolution in a group of 12 untreated
neonates with HCV infection was reported previously by
Farci et al. [6]. They observed that mono- or oligoclonal
HCV populations were associated with a high level of ALT
activity and hepatic injury, while heterogenous ones were
associated with a lower ALT activity and mild or no liver
damage [6]. In the case of children with CHC, we did not
a
b
Fig. 4 Consensus HVR1 nucleotide and amino acid sequences. The
consensus sequences were determined for populations forming phylo-
geneticclusters1and2(thepopulationsisolatedfrom6non-responders
at T0; see Online Resource 8). The sequences are named according to
patients’ numbers. Uppercase letters indicate positions with 100%
identity within one population. a Consensus nucleotide sequences.
Quasispecies-speciﬁc, single-nucleotide variations, determined in
relation to the CON-P1-01 sequence, were observed within all other
consensus sequences (shaded) and indicated next to the alignment.
b Consensus amino acid sequences. Consensus sequences of the
quasispecies grouping in cluster 1 are identical (P1-01, P1-02, P1-05,
P2-05, P2-19). Quasispecies-speciﬁc single-amino-acid variation
(12T) was only found in one consensus sequence obtained for the
population forming cluster 2 (P1-03) (shaded)
Table 2 Selection pressures acting on the HVR1 coding region in HCV populations present in patients with diverse responses to treatment
Dataset Global dN/dS ratio Codons under positive selection (numbers refer to HVR1) Codons under negative selection
(numbers refer to HVR1)
T0 T2 T0 T2 T0 T2
NR 0.672 0.707 16, 22 8, 16, 21, 22 2, 7, 20, 23 1, 2, 7, 20, 26
TR 0.993 0.935 12, 17 11, 12, 16, 17, 21 1, 2, 15, 23 1, 2, 15, 20, 23
SR 1.792 1.614 10, 11, 12, 13, 14, 16, 17, 18, 21, 22 5, 11, 12, 13, 14, 16, 17, 21, 22 1, 23 1, 2, 23, 26
NR no response; TR transient response; SR sustained response
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123observe such a correlation between ALT activity and HCV
population structure. Interestingly, our ﬁndings are also
inconsistent with previous observations made for adults
with CHC undergoing anti-HCV therapy. In that study, it
was suggested that homogeneity of HCV quasispecies at
the baseline [21, 29, 30] or dramatic reduction of HCV
genetic diversity during the ﬁrst weeks of the therapy [5]i s
associated with viral clearance. In contrast, we found that
patients with an almost homogenous HCV quasispecies at
T0 did not eliminate the virus, while the ones with heter-
ogeneous populations developed a sustained response.
Similarly to Farci et al. [5], we observed a reduction of
HCV quasispecies diversity in some sustained responders.
Taking into account differences in the course and mani-
festation of chronic hepatitis C in adults and children, one
can speculate that the mechanism underlying resistance to
anti-HCV treatment may also vary in these two groups of
patients.
HVR1 is the main target of host antibodies and is the
most variable region of the HCV polyprotein. Hence, the
stability of this region reported here seems to be a sur-
prising discovery. HVR1 homogeneity was reported
earlier in immunocompromised children and adults [10].
In the group we classiﬁed as non-responders, there were
three patients who had previously undergone immuno-
suppressive treatment due to an oncological disease who
were anti-HCV negative by fourth-generation ELISA
(P2-05, P2-10, P2-28; Table 1). However, at T0, the level
of HVR1 diversity in these children was similar to that in
anti-HCV-positive non-responders. These observations
suggest that the conservation of HVR1 in non-responders
is not caused by defects in their humoral immune
response.
An analysis undertaken by Gerotto and coworkers
showed that, in children with CHC, the degree of HVR1
variability increases continuously in parallel with the nat-
ural development of the host immune system [12]. As a
consequence, a more constant HVR1 is expected in younger
children. Since the mean age of non-responders was almost
the same as that of sustained responders (11.1 years, range
8–14, vs. 11.8 years, range 8–16, respectively), the
observed changes in HVR1 variability could not be
explained by differences in immune system development.
Statistical analysis also did not reveal any correlation
between the patients’ age and the level of HVR1 variability
within the examined group of patients or within two sub-
groups: NR and SR patients.
Only recently, a lack of HVR1 variability over a long
period of time has been reported in two immunocompetent
perinatally HCV-1a/c-infected children [13]. Both of them
were subjected to interferon alpha monotherapy, and both
failed to eliminate the virus. In addition, Gismondi and
coworkers detected almost complete conservation of the
HVR1 amino acid sequence, accompanied by a strong
negative selection operating at certain positions. A similar
observation was made with our non-responders. Gis-
mondi’s group proposed two possible explanations for this
HVR1 homogeneity: immunotolerance and adaptation of
the virus to the speciﬁc conditions within each host. The
results presented here favor latter hypothesis. In addition to
intra-quasispecies homogeneity, we identiﬁed the surpris-
ing phenomenon of inter-quasispecies conservation of
HVR1 variants in children who failed to clear the virus. It
is plausible that these variants demonstrate the highest
ﬁtness, resulting from optimal structural and/or functional
properties. Accordingly, selection would favor their con-
servation. However, a hypothetical mechanism of immu-
notolerance in NR patients cannot be ruled out. It is
probably a combination of the viral factors and the
immunological aspects of a given patient that determines
the HCV persistence. Our ﬁndings support earlier obser-
vations that variants that are inherently resistant to therapy
may be present before its onset. It is also worth mentioning
that non-responder-speciﬁc conservative HVR1 variants
were never found in populations isolated from sustained
responders. Based on the data provided by Gismondi et al.
[13], one can hypothesize that these variants remain
unchanged throughout treatment. In contrast, in children
demonstrating a sustained response, positive selection
seems to accelerate viral evolution to generate a more ﬁt
population. The high variability in these quasispecies
probably reﬂects an ongoing process of adaptation of
suboptimal variants—apparently an unsuccessful one, at
least in terms of viral survival, since these populations
were eliminated during treatment.
At present, it would be highly tentative to speculate
what speciﬁc features of the conserved HVR1 variants
underlie their superiority. It is certainly beyond the scope
of this study. Gismondi et al. predicted in silico that the
identiﬁed variants are antigenic. This suggests that the
invariability of HVR1 is not due to the lack of an adequate
humoral immune response [13]. Recently, we have
expressed the E2 gene in E. coli. HVR1 of the resulting
protein was identical to the variant most prevalent in
cluster 1. During the preliminary experiments, we were
able to detect the partially puriﬁed recombinant E2 protein
by ELISA with homologous and heterologous patient sera
[P.J., M.F., M.F., unpublished results]. Even if HVR1 alone
was not targeted by the antibodies (obviously, this could
not be concluded from the initial studies with patient sera),
other regions of E2 were, calling into question the need to
keep HVR1 unchanged. Consequently, it is presumably not
immune evasion that causes HVR1 homogeneity. For this
reason, to gain insight into the mechanisms driving HVR1
variability, attention should be focused on other processes
involving the E2 protein during the host-virus interaction.
Hepatitis C virus quasispecies in children during therapy 1985
123The same conclusion can be drawn from the distribution
of codons subjected to positive selection in our sustained
responders. Previously, two antigenic stretches (spanning
residues 3-13 and 19-25) were identiﬁed within HVR1 [22].
Together, they constitute the majority of HVR1. Surpris-
ingly, our results demonstrate that positively selected
codons prevail in the central, non-antigenic region (10–18),
and these are probably involved in maintaining HVR1
conformation and interactions with other molecules [22].
This observation indicates that adaptation to host proteins is
at least as an important factor driving HVR1 evolution in
children as diversiﬁcation caused by host antibodies.
The results presented in this paper suggest that the
degree of baseline HCV quasispecies diversity correlates
with the outcome of chronic hepatitis C treatment in chil-
dren. If conﬁrmed in a larger group of patients in the future,
this observation would be of great importance for further
optimization of the anti-HCV therapy. We also provide
another line of evidence that HVR1 diversiﬁcation and
evolution may be driven differently in pediatric patients
than in adults. This matter should be considered during
prospective clinical and virological studies.
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